Lexaria Bioscience (Lexaria Bioscience) 3-Year Book Growth Rate : -23.50% (As of Feb. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lexaria Bioscience 3-Year Book Growth Rate?

Lexaria Bioscience's Book Value per Share for the quarter that ended in Feb. 2024 was $0.00.

During the past 12 months, Lexaria Bioscience's average Book Value per Share Growth Rate was -37.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was -23.50% per year. During the past 5 years, the average Book Value per Share Growth Rate was -6.80% per year. During the past 10 years, the average Book Value per Share Growth Rate was -7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Lexaria Bioscience was 79.80% per year. The lowest was -66.10% per year. And the median was -14.10% per year.

Competitive Comparison of Lexaria Bioscience's 3-Year Book Growth Rate

For the Biotechnology subindustry, Lexaria Bioscience's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexaria Bioscience's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's 3-Year Book Growth Rate falls into.

Lexaria Bioscience 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Lexaria Bioscience (NAS:LEXXW) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Lexaria Bioscience 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexaria Bioscience (Lexaria Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXXW) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

LEXX:USA

Address

740 McCurdy Road, Suite 100, Kelowna, BC, CAN, V1X 2P7

Website

https://www.lexariabioscience.com

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.